QIAGEN and Inovio collaborate to develop companion diagnostic for novel immunotherapy targeting precancerous cervical lesions
Hilden, Germany, Germantown, Maryland, and Plymouth Meeting, Pennsylvania, May 16, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Inovio Pharmaceuticals Inc. (NASDAQ: INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV).... Read more